102
ORIGINAL CONTRIBUTIONS
nature publishing group
INFLAMMATORY BOWEL DISEASE
Expression of the High-Af nity IgG Receptor FcRI (CD64) in Patients With In ammatory Bowel Disease: A New Biomarker for Gastroenterologic Diagnostics Wolfgang Tillinger, MD1, Ruth Jilch, MD2, Bernd Jilma, MD3, Harald Brunner, MD1, Ursula Koeller, MD2, Cornelia Lichtenberger4, omas Waldhör, PhD5 and Walter Reinisch, MD4
OBJECTIVES:
We sought to determine the quantitative expression of the high-af nity Fc receptor (CD64) on polymorphonuclear neutrophils (PMNs) in in ammatory and functional conditions of the intestine and investigated its correlation with clinical and biological parameters of in ammation. The quantitative expression of CD64 was determined by uorescence-activated cell sorting analysis in patients with active or inactive in ammatory bowel disease (IBD, n= 76), infectious enterocolitis, lactose and/or fructose intolerance, and healthy subjects. The quantitative expression of CD64 in patients with active IBD (3,398±3,589 molecules per PMN, n= 27) was signi cantly higher than in healthy subjects (607±265, n= 28, P< 0.001) or in patients with lactose/fructose intolerance (531±150, n= 32, P< 0.001). The expression of CD64 correlated signi cantly with C-reactive protein (CRP, 0.65, P< 0.0001), Crohn’s disease activity index (CDAI, 0.53, P< 0.0001), and colitis activity index (CAI, 0.63, P< 0.0001) in patients with IBD. With a cutoff point of 800, CD64 had a sensitivity of 88% and a speci city of 93% in discriminating between lactose/fructose intolerance and active IBD. The quantitative expression of CD64 in patients with infectious enterocolitis (19,190±8,920, n= 22) was signi cantly higher than in patients with active IBD (P< 0.001). With a cutoff point of 10,000, CD64 showed a sensitivity of 96% and a speci city of 97% in discriminating between infectious enterocolitis and active IBD. functional intestinal disorders.
METHODS:
RESULTS:
CONCLUSIONS: CD64 could serve as a valuable tool to discriminate between IBD, infectious enterocolitis, and Am J Gastroenterol 2009; 104:102–109; doi:10.1038/ajg.2008.6
INTRODUCTION Crohn’s disease (CD) and ulcerative colitis (UC) are chronic in ammatory conditions collectively referred to as in ammatory bowel disease (IBD). ese conditions are thought to be genetically determined, overaggressive immune responses of the intestinal mucosa to normal resident bacterial constituents (1). e imbalance of the mucosal immune response involves humoral and cellular components including polymorphonuclear neutrophils (PMNs). PMN activation, followed by in ltration into the intestinal mucosa and migration across the crypt epithelium is regarded as a key feature of IBD (2). It has been estimated by fecal indium-111-labeled leukocyte 1 3
excretion that migration of PMN from the circulation to the diseased section of the intestine is increased by 10-fold or more in IBD patients (3). Once the
diagnosis of IBD has been established by endoscopic, histologic, and radiologic methods, the course of the disease is preferentially measured in terms of in ammatory activity by noninvasive tests using laboratory markers such as the white blood cell count, and C-reactive protein (CRP). However, these markers have a low speci city and show limited correlation with disease activity. More recently, the fecal protein marker calprotectin has been shown to closely correlate with macroscopic and histologic evidence of in ammation (4).
1st Medical Department, Hietzing Hospital, Vienna, Austria; 2Institute of Medical and Chemical Laboratory Diagnostics, Hietzing Hospital, Vienna, Austria; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; 4Department of Gastroenterology and Hepatology, Clinic for Internal Medicine III, University of Vienna, Vienna, Austria; 5Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria. Correspondence: Wolfgang Tillinger, MD, 1st Medical Department, Hietzing Hospital, Wolkersbergenstr. 1, A-1130 Vienna, Austria. E-mail: wolftill@mac.com Received 2 May 2008; accepted 31 July 2008 The American Journal of GASTROENTEROLOGY VOLUME 104| JANUARY 2009 doc.guandang.net

and reagents (Siemens Healthcare Diagnostics Products Ltd., Duisburg, Germany)... might serve as a new and reliable biomarker for the diagnosis and the ...
and validation of protein measurements Developing and evaluating new technical...diagnostics Summary: NCI Proteomic Technologies Programs to Support Biomarker ...
Identification of MicroRNA as Sepsis Biomarker ...,” Expert Review of Molecular Diagnostics, vol....“Serum miR-146a and miR223 as potential new ...
9 ? HE4 PElvIC MASS is a new biomarker for OEC. HE4 is used as an... USA AbbreviAtions 24 3 Key Points 25 www.abbottdiagnostics.com 1-877-...
Identification of MicroRNA as Sepsis Biomarker ...,” Expert Review of Molecular Diagnostics, vol....“Serum miR-146a and miR223 as potential new ...
热门文档